

DAFTAR PUSTAKA

1. G. Yuan, J. Chen, D. Wu, and C. Gao, "Neoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of enneking stage II: a retrospective study," *OncoTargets and Therapy*, vol. 10, pp. 2745–2750, 2017.
2. G. Ottaviani and N. Jaffe, "The epidemiology of osteosarcoma," *Cancer Treatment and Research*, vol. 152, pp. 3–13, 2009.
3. P. Anderson, "Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma," *Future Oncology*, vol. 2, no. 3, pp. 333–343, 2015.
4. A. Luetke, P. A. Meyers, I. Lewis, and H. Juergens, "Osteosarcoma treatment - where do we stand? A state of the art review," *Cancer Treatment Reviews*, vol. 40, no. 4, pp. 523–532, 2014.
5. C. Marcove, V. Miké, J. V. Hajek, A. G. Levin, and R. V. P. Hutter, "Osteogenic sarcoma under the age of twenty-one," *The Journal of Bone & Joint Surgery*, vol. 52, no. 3, pp. 411–423, 1970. M. S. Isakoff, S. S. Bielack, P. Meltzer, and R. Gorlick, "Osteosarcoma: current treatment and a collaborative pathway to success," *Journal of Clinical Oncology*, vol. 33, no. 27, p. 3029, 2015.
6. A. J. Provisor, L. J. Ettinger, J. B. Nachman et al., "Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group," *Journal of Clinical Oncology*, vol. 15, no. 1, pp. 76–84, 1997.
7. A. M. Goorin, D. J. Schwartzentruber, M. Devidas et al., "Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651," *Journal of Clinical Oncology*, vol. 21, no. 8, pp. 1574–1580, 2003.
8. Chu S, Karimi S, Peck KK, Yamada Y, Lis E, Lyo J, et al. Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging evaluation of tumor response to radiation therapy. *Spine*. 2013;38:E1418–E24.
9. Chu S, Karimi S, Peck KK, Yamada Y, Lis E, Lyo J, et al. Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging evaluation of tumor response to radiation therapy. *Spine*. 2013;38:E1418–E24.

10. Guo J, Reddick WE, Glass JO, Ji Q, Billups CA, Wu J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. *Cancer*. 2012;118:3776–85.
11. Wakabayashi H, Saito J, Taki J, Hashimoto N, Tsuchiya H, Gabata T, et al. Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy. *Skelet Radiol*. 2016;45:87–95.
12. Schajowicz F, Sissons HA, Sobin LH. The World Health Organization's histologic classification of bone tumors. A commentary on the second edition. *Cancer*. 1995;75(5):1208–1214
13. Salter, Robert B. Textbook of disorders and injuries of the musculoskeletal system. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.p.400-3.
14. Skinner, Harry B. Current diagnosis & treatment in orthopaedics. Lange Medical Book. 3rd ed. New York: McGraw-Hill; 2003.p.312-8
15. Patterson FR. 2008. Osteosarcoma. In: Timothy AD, editor. Orthopaedic Surgery essential. oncology and basic science. Philadelphia: Lippincott Williams & Wilkins; 2008.p.177-87.
16. Solomon L, Warwick D, Nayagam S. Apley's system of orthopaedics and fractures. 8th ed. New York: Oxford University Press Inc; 2001.p.185-218.
17. Gebhardt, Mark C, Hornicek, Francis J. Osteosarcoma. Orthopaedic knowledge update musculoskeletal tumors. American Academy of Orthopaedic Surgeons. 1st ed. New York: McGraw-Hill; 2002.p.175-82
18. Bechler JR, Robertson WW, Meadows AT, Womer RB. Osteosarcoma as a second malignant neoplasm in children. *J Bone Joint Surg Am* 1992;74:1079-83.
Wittig, James C, Bickels J, Priebat D, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. A peer reviewed Journal of American Academic of Family Physicians 2002
19. Tsuji Y, Kusuzaki K, Kanemitsu K, et al. Calcaneal osteosarcoma associated with werner syndrome. *The Journal of Bone and Joint Surgery* 2000;82:9-12.
20. Dorfman, HD and Czerniak, B. Bone Tumor: Osteosarcoma.. Philadelphia: Elsevier Saunders; 2016. Page.200-342.

21. Raymond AK, Ayala AG, Knuutila S. Secondary osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology and genetics of tumours of the soft tissues and bones. IARC Press; Lyon: 2002. pp. 264–270.
22. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. *Cancer*. 1993;72(11):3227–3238.
23. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. *J Clin Oncol*. 1997;15(1):76–84.
24. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. *Lancet*. 1997;350(9082):911–917.
25. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. *Ann Oncol*. 2001;12(8):1145–1150.
26. Kawiya S. 2009. Osteosarcoma, Diagnosis dan Penanganannya. http://ejournal.unud.ac.id/abstrak/dr%20siki_9.pdf
27. Patel SR, Benjamin RS. 2008. Soft Tissue and Bone Sarcomas and Bone Metastases. dalam: Kasper DL et al. *Harrison's Principles of Internal Medicine 17th ed*. USA: McGRAW-HILL.
28. Picci P. 2007. Osteosarcoma (Osteogenic Sarcoma). *Orphanet Journal of Rare Disease*. <http://www.OJRD.com/content/2/1/6>, 30 Januari 2011.
29. Springfield D. 2006. Orthopaedics. dalam: Brunicaudi FC. *Schwartz's Manual of Surgery 8th ed*. USA: McGRAW-HILL
30. Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. *Clin Orthop Relat Res*. 2000;376:200–8.
31. Holscher HC, Bloem JL, Vanel D, Hermans J, Nooy MA, Taminiau AH, et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. *Radiology*. 1992;182:839–44.

32. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. *Cancer*. 1995;75:1084–93.
33. Wellings RM, Davies AM, Pynsent PB, Carter SR, Grimer RJ. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. *Clin Radiol*. 1994;49:19–23.
34. Laux CJ, Berzaczy G, Weber M, Lang S, Dominkus M, Windhager R, et al. Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome. *Int Orthop*. 2015;39:97–104.
35. Byun BH, Kong CB, Lim I, Kim BI, Choi CW, Lim SM. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18F-FDG PET/CT and MRI. *J Nucl Med*. 2014;55.
36. Chu S, Karimi S, Peck KK, Yamada Y, Lis E, Lyo J, et al. Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging evaluation of tumor response to radiation therapy. *Spine*. 2013;38:E1418–E24.
37. Guo J, Reddick WE, Glass JO, Ji Q, Billups CA, Wu J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. *Cancer*. 2012;118:3776–85.
38. Wakabayashi H, Saito J, Taki J, Hashimoto N, Tsuchiya H, Gabata T, et al. Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy. *Skelet Radiol*. 2016;45:87–95.
39. Amit P, Patro DK, Basu D, Elangovan S, Parathasarathy V (2014) Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas. *Am J Clin Oncol-Canc*37:384–390, 2014.
40. Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. *J Magn Reson Imaging* 10:223–232. [https://doi.org/10.1002/\(sici\)1522-2586\(199909\)10:3<223::aid-jmri2>3.0.co;2-s](https://doi.org/10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s)
41. Verstraete KL, Lang P (2000) Bone and soft tissue tumors: the role of contrast agents for MR imaging. *Eur J Radiol* 34:229–246. [https://doi.org/10.1016/s0720-048x\(00\)00202-3](https://doi.org/10.1016/s0720-048x(00)00202-3)

42. Hotker AM, Garcia-Aguilar J, Gollub MJ (2014) Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. *Dis Colon Rectum* 57:790–799. [https://doi.org/ 10.1097/DCR.0000000000000127](https://doi.org/10.1097/DCR.0000000000000127)
43. Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. *Cancer* 6:963–968. [https://doi.org/10.1002/ 1097-0142\(195309\)6:5<963::aid-cncr2820060515>3.0.co;2-q](https://doi.org/10.1002/1097-0142(195309)6:5<963::aid-cncr2820060515>3.0.co;2-q)
44. Ren L, Mendoza A, Zhu J et al (2015) Characterization of the meta- static phenotype of a panel of established osteosarcoma cells. *Oncotarget* 6:29469–29481. <https://doi.org/10.18632/oncotarget.5177>
45. Zhang, BT., Zheng, Q., Liu, L. et al. Response Monitoring to Neoadjuvant Chemotherapy in Osteosarcoma Using Dynamic Contrast-Enhanced MR Imaging. *SN Compr. Clin. Med.* 1, 319–327 (2019). <https://doi.org/10.1007/s42399-019-00059-4>
46. Sun, N. N., Liu, C., Ge, X. L., & Wang, J. (2018). Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy. *Diagnostic and interventional radiology (Ankara, Turkey)*, 24(4), 195–202. <https://doi.org/10.5152/dir.2018.17369>
47. Intven M, Reerink O, Philippens MEP. Dynamic contrast enhanced MR imaging for rectal can- cer response assessment after neo-adjuvant chemoradiation. *J Magn Reson Imaging* 2015; 41:1646–1653.
48. Cooper RA, Carrington BM, Loncaster JA, et al. Tumor oxygenation levels correlate with dy- namic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. *Radiother Oncol* 2000; 57:53–59.
49. King AD, Thoeny HC. Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitations. *Cancer Imaging* 2016; 16:23.
50. Lee HY, Kim N, Goo JM, et al. Perfusion parame- ters as potential imaging biomarkers for the early prediction of radiotherapy response in a rat tumor model. *Diagn Interv Radiol* 2016; 22:231–240.
51. Chikui T, Kitamoto E, Kawano S, et al. Pharmaco- kinetic analysis based on dynamic contrast-en- hanced MRI for evaluating tumor response to preoperative therapy for oral cancer. *J Magn Reson Imaging* 2012; 36:589–597.
52. Kim S, Loevner LA, Quon H, Kilger A, Sherman E, Weinstein G, et al. Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and

- neck using dynamic contrast-enhanced MR imaging. *Am J Neuroradiol.* 2010;31:262–8.
53. Kim SH, Lee JM, Gupta SN, et al. Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. *J Magn Reson Imaging* 2014; 40:730–737.
54. Zahra MA, Hollingsworth KG, Sala E, et al. Dynamic contrast-enhanced MRI as a predictor of tumor response to radiotherapy. *Lancet Oncol* 2007; 8:63–74.
55. Giesel FL, Bischoff H, von Tengg-Kobligk H, Weber MA, Zechmann CM, Kauczor HU, et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. *Chest.* 2006;129(6):1570–6.
56. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. *Radiology.* 1990;175:791–796.
57. Amit, P., Patro, D. K., Basu, D., Elangovan, S., & Parathasarathy, V. (2014). Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas. *American journal of clinical oncology*, 37(4), 384–390. <https://doi.org/10.1097/COC.0b013e31827b4f6f>
58. Guo W., Luo D., Chen X., Lin M., Li L., Zhao Y., Yang L., Hu L., Zhao X., Zhou C. Dynamic contrast-enhanced magnetic resonance imaging for pretreatment prediction of early chemo-radiotherapy response in larynx and hypopharynx carcinoma. *Oncotarget.* 2017; 8: 33836-33843.
59. Johansen R, Jensen LR, Rydland J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. *J Magn Reson Imaging.* 2009;29:1300–1307.
60. Sharma A, Sharma S, Sood S, Seam RK, Sharma M, Fotedar V. DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma: a preliminary report. *Pol J Radiol.* 2018 May 18;83:e220-e228. doi: 10.5114/pjr.2018.76271. PMID: 30627239; PMCID: PMC6323583.
61. Powell, C, Schmidt, M, Borri, M Changes in functional imaging parameters following induction chemotherapy have important implications for individualized patient-based treatment regimens for advanced head and neck cancer. *Radiother Oncol* 2013; 106: 1112–1117.